Document is current
Any future updates will be listed below
-
Authors
Kiemel, Dominik
Kroell, Ann-Sophie Helene http://orcid.org/0000-0001-9986-0737
Denolly, Solène http://orcid.org/0000-0003-1739-0079
Haselmann, Uta
Bonfanti, Jean-François
Andres, Jose Ignacio
Ghosh, Brahma http://orcid.org/0000-0003-2288-8293
Geluykens, Peggy
Kaptein, Suzanne J. F. http://orcid.org/0000-0002-7935-0219
Wilken, Lucas http://orcid.org/0000-0002-5678-3089
Scaturro, Pietro http://orcid.org/0000-0001-9098-3087
Neyts, Johan http://orcid.org/0000-0002-0033-7514
Van Loock, Marnix http://orcid.org/0000-0003-4151-4588
Goethals, Olivia
Bartenschlager, Ralf http://orcid.org/0000-0001-5601-9307
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB 1129 project number 240245660)
Wellcome Trust (106327/Z/14, 089328/Z/09)
Agentschap Innoveren en Ondernemen (IWT 150863, IWT 150863)
Wellcome Trust (106327/Z/14, 089328/Z/09)
Agentschap Innoveren en Ondernemen
- License Information
-
More Information
Article History
Received: 26 June 2023
Accepted: 5 July 2024
First Online: 19 July 2024
Competing interests
: J.-F.B., S.J.F.K., J.N., M.vL., and O.G. have been named inventor in a patent application claiming the discovery of this class of antiviral molecules as DENV replication inhibitors (WO 2017/167951), which was filed by applicants Janssen Pharmaceuticals, Inc. and Katholieke Universiteit Leuven, and has been granted in certain countries. O.G., J.-F.B., M.vL., S.J.F.K. and J.N. have been named inventors in a pending patent application relating to the use of substituted indole derivatives and substituted indoline derivatives in the manufacture of a medicament for the treatment or the prevention of dengue disease in an individual at risk of being infected by DENV and to a method for the treatment or the prevention of dengue in an individual at risk of being infected by DENV, which was filed by Applicants Janssen Pharmaceuticals, Inc. and Katholieke Universiteit Leuven (WO 2021/094563). O.G., B.G. and M.vL. are all full-time employees of Janssen and potential stockholders of Johnson and Johnson. The other authors declare no competing interests.
